For elderly or comorbid patients, the high toxicity of powerful, time-limited combination therapies can outweigh their efficacy. A less harsh, continuous monotherapy is often preferable as it better preserves quality of life, even if it doesn't offer a treatment-free interval or a theoretical "100% life back."

Higher death rates observed in the triplet therapy arms of recent CLL trials (e.g., AMPLIFY) were significantly impacted by the COVID-19 pandemic, as anti-CD20 antibodies increase infection risk. This historical context complicates the interpretation and generalizability of the toxicity data in a post-pandemic era.

Adding obinutuzumab later to acalabrutinib/venetoclax therapy—and only for patients with an incomplete response—achieves the same remission rates as upfront administration. This delayed approach improves overall survival by avoiding early, severe infections, particularly COVID-19, associated with the antibody.

Initial studies combining menin inhibitors with venetoclax/azacitidine showed high remission rates but also high mortality. Using each agent at its full, 28-day dose caused severe, fatal myelosuppression, forcing protocol amendments to shorten drug exposure to manage toxicity.

While adding a menin inhibitor to the azacitidine/venetoclax doublet for older/unfit AML patients increases response rates, it leaves little reserve for marrow function. This can lead to increased risk of early, fatal complications like infection or bleeding, requiring careful dose management.

In the AMPLIFY trial, the acalabrutinib-venetoclax (AV) arm showed superior overall survival. This was heavily influenced by the COVID-19 pandemic, as regimens containing the anti-CD20 antibody obinutuzumab (AVO and chemo) had significantly more fatal COVID cases, making the antibody a liability during that period.

The CLL17 study reveals that continuous ibrutinib, fixed-duration venetoclax/obinutuzumab, and fixed-duration venetoclax/ibrutinib all yield identical progression-free survival rates at three years. This finding empowers clinicians to choose a strategy based on patient preference (continuous vs. fixed-duration) without compromising near-term efficacy.

An MD Anderson study showed that delaying the addition of obinutuzumab to an acalabrutinib-venetoclax regimen achieved similar deep remission rates (uMRD) as upfront administration. This sequencing strategy significantly reduced severe neutropenia (52% vs 12%) and infections, making the potent combination safer.

The CLL17 trial revealed a counterintuitive finding: unfit patients had worse outcomes on continuous ibrutinib, likely due to toxicity-related discontinuations. The logistically harder venetoclax-obinutuzumab fixed-duration regimen produced equal efficacy in both fit and unfit patients, making it a better choice for the less fit.